On Thursday, Keros Therapeutics, Inc. (NASDAQ:KROS) voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial Phase 2 trial of cibotercept (KER-012) in ...
LEXINGTON, MA / ACCESSWIRE / March 4, 2020 / Keros Therapeutics, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for patients suffering ...
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial ...
Keros is a pre-revenue biotech with two therapies in phase 2 trials. The company focuses on treatments for blood and musculoskeletal disorders. Management says the company has enough cash to fund ...
Hosted on MSN
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
Shares of Keros Therapeutics, Inc. (KROS) traded 14% higher on Thursday morning after the company adopted a poison pill plan to fend off hostile takeovers by a number of investors that have rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback